Scholarlink

Background <p>Liver cancer represents a significant health burden, with hepatocellular carcinoma (HCC) accounting for most cases. Despite treatment advances, HCC prognosis remains poor, underscoring the need for a deeper understanding of its molecular mechanisms.</p> Aim <p>This study explores the role of leukotriene A4 hydrolase (LTA4H) and its product, leukotriene B4 (LTB4), in HCC progression.</p> Methods <p>Bioinformatic analysis was used to evaluate the expression profiles of LTA4H and LTB4 receptors, LTB4R and LTB4R2, in human HCC samples. 2D and 3D cultures of HCC cells were treated with the selective LTA4H inhibitor SC-57461A to assess cell viability, proliferation, migration, invasion, and apoptosis. In vivo studies in nude mice bearing human HCC xenografts treated with SC-57461A were performed to evaluate tumor growth and proliferation markers (PCNA and Ki-67).</p> Results <p>Gene expression analysis revealed significant upregulation of LTA4H and its receptors in HCC tissues compared to healthy liver samples. 2D and 3D cultures of human HCC cells treated with SC-57461A showed reduced cell viability, migration, invasion, and proliferation and apoptosis. In mice orthotopically implanted with human HCC&#xa0;cells and treated with SC-57461A, tumor growth rate, size, and proliferation marker levels were markedly decreased.</p> Conclusions <p>This study identifies LTA4H as a critical factor in HCC, suggesting its potential as a prognostic biomarker. The findings also highlight the promise of LTA4H inhibitors as a new approach for developing more effective treatments for liver cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unraveling the Role of Leukotriene A4 Hydrolase in Hepatocellular Carcinoma: Implications for Targeted Therapy and Tumor Progression

  • 期刊论文

  • 发表日期：

    2025年6月28日

查看全文
  • Lucía Oviedo Bustos,
  • Magalí Frattini,
  • Carla G. Comanzo,
  • Marina C. Vera,
  • Nicolás F. Palma,
  • Alejo M. Capiglioni,
  • María Paula Ceballos,
  • Anabela C. Ferretti,
  • Ariel D. Quiroga,
  • María de Luján Alvarez

摘要

Background

Liver cancer represents a significant health burden, with hepatocellular carcinoma (HCC) accounting for most cases. Despite treatment advances, HCC prognosis remains poor, underscoring the need for a deeper understanding of its molecular mechanisms.

Aim

This study explores the role of leukotriene A4 hydrolase (LTA4H) and its product, leukotriene B4 (LTB4), in HCC progression.

Methods

Bioinformatic analysis was used to evaluate the expression profiles of LTA4H and LTB4 receptors, LTB4R and LTB4R2, in human HCC samples. 2D and 3D cultures of HCC cells were treated with the selective LTA4H inhibitor SC-57461A to assess cell viability, proliferation, migration, invasion, and apoptosis. In vivo studies in nude mice bearing human HCC xenografts treated with SC-57461A were performed to evaluate tumor growth and proliferation markers (PCNA and Ki-67).

Results

Gene expression analysis revealed significant upregulation of LTA4H and its receptors in HCC tissues compared to healthy liver samples. 2D and 3D cultures of human HCC cells treated with SC-57461A showed reduced cell viability, migration, invasion, and proliferation and apoptosis. In mice orthotopically implanted with human HCC cells and treated with SC-57461A, tumor growth rate, size, and proliferation marker levels were markedly decreased.

Conclusions

This study identifies LTA4H as a critical factor in HCC, suggesting its potential as a prognostic biomarker. The findings also highlight the promise of LTA4H inhibitors as a new approach for developing more effective treatments for liver cancer.